Krystal Biotech, Inc. KRYS
345.82
0.86
0.25%
as of 25 Sep
- Market cap
- $10.2B
- P/E
- 41.9×
Follow KRYS
Growth Flags
show if company had growth for consecutive years
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
34.82 | 50.54 | 694.22 | — | — | — | — | — | — | — |
P/S ratio |
18.34 | 15.42 | 0.00 | — | — | — | — | — | — | — |
P/FCF ratio |
37.69 | 37.58 | 0.00 | — | — | — | — | — | — | — |
P/Operating CF |
92.07 | 84.76 | (469.19) | — | — | — | — | — | — | — |
P/B ratio |
5.85 | 4.73 | 4.36 | — | — | — | — | — | — | — |
Price to Tangible BV |
5.85 | 4.73 | 4.36 | — | — | — | — | — | — | — |
EV/Sales |
16.21 | 13.36 | 0.00 | — | — | — | — | — | — | — |
EV/EBITDA |
37.58 | 53.57 | 0.00 | — | — | — | — | — | — | — |
EV/Operating CF |
31.40 | 31.45 | (32.22) | — | — | — | — | — | — | — |
EV/FCF |
33.31 | 32.57 | (4,744.59) | — | — | — | — | — | — | — |
Quick Ratio |
9.28 | 6.89 | 17.35 | 13.14 | 17.02 | 17.56 | 58.22 | 43.05 | 77.49 | 44.72 |
Current Ratio |
9.95 | 7.28 | 17.76 | 13.30 | 17.18 | 17.80 | 58.88 | 43.39 | 77.99 | 50.44 |
Net Debt/EBITDA |
(4.93) | (8.25) | 5.13 | 2.62 | 6.58 | 8.60 | 9.09 | 9.49 | 10.44 | 0.07 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.32% | 1.11% | 1.06% | 1.33% | 0.00% | 0.00% | 84.46% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 6.38 |
Asset Turnover |
0.33 | 0.31 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.98 | 1.38 | (8.12) | 0.72 | 0.69 | 0.81 | 0.98 | 0.87 | 0.49 | 1.14 |
Capex/Depreciation |
(1.76) | (0.63) | 14.92 | (15.65) | (24.68) | (8.02) | (5.87) | (15.84) | (9.13) | (7.50) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 18.91% | 10.34% | 1.68% | (25.09%) | (15.71%) | (13.00%) | (12.08%) | (13.39%) | (32.76%) | (4.76%) | |
| 17.14% | 9.51% | 1.59% | (23.63%) | (14.85%) | (12.38%) | (11.74%) | (13.10%) | (30.29%) | (4.40%) | |
ROIC |
25.73% | 11.78% | (27.80%) | (60.32%) | (26.27%) | (85.47%) | (114.90%) | (508.36%) | 0.00% | (341.81%) |
Return on Tangible Assets |
19.10% | 11.21% | 1.53% | (27.09%) | (13.15%) | (11.07%) | (9.50%) | (9.63%) | (16.01%) | (53.76%) |
Average Days of Receivables |
119.52 | 131.60 | 302.66 | — | — | — | — | — | — | — |
Research and Development Expense of Revenue |
14.92% | 18.44% | 91.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
37.71% | 39.11% | 193.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
14.01% | 16.91% | 78.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.13 | 0.14 | 0.16 | — | — | — | — | — | — | — |
Graham Number |
81.93 | 48.05 | 10.78 | — | — | — | — | — | — | — |
Earnings Yield |
2.87% | 1.98% | 0.14% | — | — | — | — | — | — | — |
Free Cash Flow Yield |
2.65% | 2.66% | (0.02%) | — | — | — | — | — | — | — |
Revenue per Share |
13.44 | 10.16 | 1.87 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
6.94 | 4.32 | (3.27) | (3.95) | (2.16) | (1.39) | (1.18) | (0.84) | (0.73) | (1.49) |
Capex per Share |
(0.40) | (0.15) | 3.25 | (2.08) | (3.08) | (0.79) | (0.40) | (0.20) | (0.04) | (0.02) |
Free Cash Flow per Share |
6.54 | 4.17 | (0.02) | (6.02) | (5.24) | (2.18) | (1.58) | (1.04) | (0.76) | (1.51) |
Cash per Share |
28.60 | 20.90 | 19.60 | 14.87 | 19.74 | 14.44 | 12.18 | 9.98 | 9.25 | 2.19 |
Shareholders Equity per Share |
42.14 | 33.10 | 28.68 | 20.49 | 26.74 | 15.55 | 12.76 | 10.11 | 9.23 | 0.33 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
42.14 | 33.10 | 28.68 | 20.49 | 26.74 | 15.55 | 12.76 | 10.11 | 9.23 | 0.33 |
Free Cash Flow |
189.35 | 119.18 | (0.60) | (153.55) | (116.27) | (40.93) | (25.09) | (11.68) | (4.10) | (1.33) |
Working Capital |
921.66 | 640.05 | 554.82 | 354.93 | 416.53 | 259.61 | 192.55 | 110.05 | 49.27 | 2.13 |
Capital Expenditures |
(11.52) | (4.24) | 88.20 | (52.98) | (68.34) | (14.84) | (6.40) | (2.23) | (0.21) | (0.01) |
Net Current Asset Value |
910.37 | 632.59 | 548.20 | 347.56 | 409.55 | 256.30 | 189.77 | 109.76 | 49.27 | 0.28 |
EV/EBIT |
39.11 | 59.04 | 0.00 | — | — | — | — | — | — | — |
Capex to Sales |
0.03 | 0.01 | (1.74) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
52.64% | 30.69% | 21.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
44.24 | 68.13 | 0.00 | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.04 | 0.04 | 0.04 | 0.02 | 0.02 | 0.06 | 0.13 | 0.05 | 0.12 | 0.15 |
Cash ROIC |
2.45% | (2.06%) | (19.07%) | (28.86%) | (15.43%) | (10.05%) | (6.80%) | (5.54%) | (4.13%) | (32.65%) |
Accounts Receivable Turnover |
3.35 | 3.96 | 0.00 | — | — | — | — | — | — | — |
Accounts Payable Turnover |
5.61 | 4.40 | 0.76 | 0.66 | 0.53 | 1.18 | 1.02 | 0.26 | 0.20 | 0.02 |
Inventory Turnover |
0.69 | 1.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
51.28 | 90.70 | 487.45 | 358.34 | 1,107.00 | 415.09 | 382.61 | 2,298.72 | 3,062.83 | 7,665.00 |
Days of Inventory on Hand |
640.96 | 482.30 | 824.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
116.09 | 73.39 | — | — | — | — | — | — | — | — |
Average Payables |
4.11 | 4.56 | 4.06 | 6.19 | 5.25 | 1.56 | 0.95 | 0.54 | 0.12 | 0.12 |
Average Inventory |
33.49 | 16.75 | — | — | — | — | — | — | — | — |
Average Assets |
1,194.82 | 937.10 | 688.40 | 592.37 | 468.57 | 259.93 | 162.57 | 83.12 | 26.15 | 26.15 |
Average Common Equity |
1,082.97 | 862.51 | 650.44 | 557.90 | 442.83 | 247.50 | 158.07 | 81.35 | 24.18 | 24.18 |
Columns are period end dates